Browsing: oncology

Amgen stock sits at the intersection of mature biologic franchises and a broad late-stage pipeline that is increasingly focused on oncology and cardiometabolic diseases. The California-based biotechnology group Amgen Inc. (ISIN US0311621009) combines steady cash generation from legacy drugs such as Enbrel and Prolia with new assets in cancer and obesity, giving investors a blend…